Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $250
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz maintains an Equal-Weight rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $164 to $250.
June 25, 2024 | 9:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained its Equal-Weight rating on Alnylam Pharmaceuticals but raised the price target significantly from $164 to $250.
The significant increase in the price target from $164 to $250 by a reputable analyst at Morgan Stanley is likely to positively impact investor sentiment and could lead to a short-term increase in ALNY's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100